{"id":200473,"name":"GENENTECH","slug":"genentech","state":"DC","country":"United States of America","description":"Biotechnology company","totalSpending":1100000,"filings":32,"yearlySpending":[{"year":2018,"income":120000},{"year":2019,"income":120000},{"year":2020,"income":120000},{"year":2021,"income":120000},{"year":2022,"income":140000},{"year":2023,"income":160000},{"year":2024,"income":160000},{"year":2025,"income":160000}],"issues":["HCR","MMM","PHA","MED"],"firms":["RIVENDELL GROUP LLP"],"lobbyists":["NICK KOLOVOS","MATTHEW BERZOK"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["HR 4710, 340B Pause Act, and issues relating generally to the 340B Drug Discount Program; issues relating to drug pricing policies.","HR 4710, 340B Pause Act and other issues relating generally to the 340B Drug Discount Program; issues relating to Medicare and Medicaid coverage and a reimbursement.","Prescription Drug User Fee Act reauthorization.","issues and legislation relating to 340B drug discount program; issues relating to drug pricing; the Pandemic and All-Hazards Preparedness Act (PAHPA)","MMM - issues and legislation relating generally to the 340B Drug Discount Program; issues relating to Medicare and Medicaid coverage and reimbursement"],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}